China SXT Pharmaceuticals
SXTC
1 hedge funds and large institutions have $78K invested in China SXT Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
50% less funds holding
Funds holding: 2 → 1 (-1)
82% less capital invested
Capital invested by funds: $436K → $78K (-$358K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$94K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$75K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$39K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$31K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Renaissance Technologies
New York
| $52K | – | – | – |
|
|
VF
2
Virtu Financial
New York
| $26K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$94K | -1 | Closed |
|
|
4
Acadian Asset Management
Boston,
Massachusetts
| – | -$31K | – | – |
|
|
CAN
5
Cetera Advisor Networks
El Segundo,
California
| – | -$6K | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$75K | – | – |
|
7
Citigroup
New York
| – | -$10K | – | – |
|
8
Geode Capital Management
Boston,
Massachusetts
| – | -$7K | – | – |
|
9
Millennium Management
New York
| – | -$3K | – | – |
|
10
Squarepoint
New York
| – | -$5K | – | – |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$39K | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$15K | – | – |
|
SXTC Hedge Fund Activity: Q2 2022 in Review
1 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q2 2022, worth a combined $78K — down 82% from $436K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SXTC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, exiting entirely with an estimated $94K sold.
- 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q2 2022, down from 2 in Q1 2022.
- Funds reported $78K of China SXT Pharmaceuticals stock for Q2 2022, down 82% quarter-over-quarter.
- 0 funds opened new China SXT Pharmaceuticals positions in Q2 2022 and 1 closed out, a net change of -1 holder.
- The largest China SXT Pharmaceuticals seller in Q2 2022 was Susquehanna International Group, an estimated $94K sold.
Based on aggregated 13F filings for Q2 2022.